From 13 till 17 September 2024: HIGHLIGHTS FROM ESMO
Your direct line with Barcelona
The European Society of Medical Oncology (ESMO) 2024 brings together leading experts in the different fields of cancer from around the world. And this year they gather together in Barcelona, Spain. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
Presidential highlights
Prof Domenica Lorusso, a gynaecological oncologist at Humanitas San Pio X, Milan, Italy, presented findings from the ENGOT-cx11/GOG-3047/KEYNOTE-A18 study during the presidential session.
The study evaluated the novel use
Daily highlights in gynaeco
In this video, Prof Dr Els Van Nieuwenhuysen, gynaecological oncologist at the University Hospitals Leuven discusses four clinical trials that were presented during the proffered paper session on gynaecological cancer
In this video, Prof Dr Hannelore Denys discusses and comments on the data of some exciting studies presented at ESMO 2024 during the Mini Oral session on gynaecological cancer.
Prof Dr Christine Gennigens, a medical oncologist at the University Hospital of CHU de Liège, focused on two studies presented during the mini oral session 2 on gynaecological cancers.
In-depth stories about gynaeco
In this video, Dr Nicum discusses these data with Prof Dr Christine Gennigens. ICON-9 included patients with relapsed, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer who received no more
In this video, Prof Dr Hannelore Denys (Ghent University Hospital, Ghent, Belgium) discusses the final overall survival (OS) data of this study presented at ESMO 2024.
In ATALANTE, 614
Prof Antonio González Martín, medical oncologist and director of the Cancer Center at the University of Navarra, presented long-term results from the PRIMA-ENGOT-OB26-GLG3012 study. This phase III trial involved patients
In this video, Prof Dr Toon Van Gorp discusses the data of the ENGOT-EN11/GOG-3053/KEYNOTE B-21 that he presented at ESMO 2024 and puts them in the broader perspective of the
Gynaeco poster selection
During ESMO 2024, results were presented of an exploratory analysis of this trial looking at the effect on PFS in function of baseline clinical factors (i.e., age, BMI, ECOG performance
Made possible with the financial support of our partners.
All videos are developed independently and are non-promotional.
